BioSpace News Archive

SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced it has received its eighth ANDA approval from the US Food and Drug Administration (FDA).

The New England Journal of Medicine published detailed results from the Phase 3 ADMIRAL trial, which found that Astellas Pharma Inc.'s (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) XOSPATA® (gilteritinib) demonstrated significantly longer Overall Survival (OS) than salvage chemotherapy in adult patients with relapsed (disease that has returned) or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation

SignPath Pharma (Salt Lake City UT) today announced the first commercial out-license of its proprietary CorreQT technology platform. SignPath entered into an agreement with Rain Therapeutics (Newark CA), which licenses SignPath’s CorreQT technology for use in conjunction with Rain’s proprietary lead compound, Tarlox® (tarloxotinib,) a potent pan-ErbB inhibitor in development as a treatment in various cancer indications.

With Open Enrollment for individual consumers beginning tomorrow, November 1, Independence Blue Cross will continue to provide a wide range of health plans to meet the needs of the community.

Maxar Technologies (NYSE:MAXR) (TSX:MAXR), a trusted partner and innovator in Earth Intelligence and Space Infrastructure, today announced that its stockholders voted in favor of the Company’s Tax Benefit Preservation Plan.

SP Industries, Inc., a Harbour Group company, acquired Irta Dosificacio I Technologia S.L. i-Dositecno (“i-Dositecno”), Jeff Fox, Harbour Group’s chairman and chief executive officer, announced today.

Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 7, 2019.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced the outcome of its two exploratory Phase 2 clinical studies evaluating the efficacy and safety of its once-daily oral and intravenous (IV) modernized tetracycline omadacycline in patients with two common forms of urinary tract infections (UTI).

Consumers Benefit from Doctor-Directed Clear Aligner Treatment with Superior Invisalign Technology and Proven Outcomes for Broadest Range and Scope of Malocclusion

Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2019 financial and operating results following the close of U.S. financial markets on Thursday, November 7, 2019.